A new study conducted by the Tokyo Metropolitan Institute of Public Health, and published in the newest issue of the Journal of Pharmacy and Pharmacology, has found that cannabinoids can reduce up to 90% of skin cancer in just a 20 week period.
For the study, researchers used synthetic cannabinoids (natural, cannabis-derived cannabinoids are typically even more effective) on mice with skin cancer in a 20 week study, and found that the cannabinoids had a hugely positive effect, reducing skin cancer by up to 90% as well as “inhibiting tumor promotion”.
This is the first report indicating the structure–activity relationships for the anti-inflammatory activity of synthetic cannabinoids on TPA-induced inflammation in mice. Naphthoylindoles, JWH-018, -122 and -210 [synthetic cannabinoids], had the most potent anti-inflammatory activity and also markedly inhibited tumour promotion by TPA in the two-stage mouse skin carcinogenesis model. The present results suggest that synthetic cannabinoids, such as JWH-018, -122 and -210, may be used as cancer chemopreventive agents in the future.